title: Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
abstract: BACKGROUND
  Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor of the pancreas with poor prognosis. The lack of understanding of the molecular mechanisms of PDAC and biomarkers for early diagnosis might be two of the reasons for the poor prognosis of PDAC.
  
  
  METHODS
  ILK and ERP29 protein expressions in PDAC, peritumoral tissues, benign pancreatic lesions, and normal pancreatic tissues were measured by immunohistochemistry and the clinical and pathological significances of ILK and ERP29 in PDAC were analyzed.
  
  
  RESULTS
  The percentages of positive ILK and negative ERP29 expressions were significantly higher in PDAC tumors than in peritumoral tissues, benign pancreatic tissues, and normal pancreatic tissues (P < 0.01). Benign pancreatic lesions with positive ILK and negative ERP29 expressions exhibited dysplasia or intraepithelial neoplasia. The percentage of cases with positive ILK and negative ERP29 expressions was significantly lower in PDAC patients without lymph node metastasis and invasion, and having TNM stage I/II disease than in patients with lymph node metastasis, invasion, and TNM stage III/IV disease (P < 0.05 or P < 0.01). Kaplan-Meier survival analysis showed that positive ILK and negative ERP29 expressions were significantly associated with survival in PDAC patients (P < 0.001). Cox multivariate analysis revealed that positive ILK and negative ERP29 expressions were independent poor prognosis factors in PDAC patients.
  
  
  CONCLUSIONS
  Positive ILK and negative ERP29 expressions are associated with the progression of PDAC and poor prognosis in patients with PDAC.
authors.affiliation: Department of General Surgery, The Fourth People's Hospital of Changde, Changde, 415000, Hunan, People's Republic of China.
authors.forename: K
authors.initials: K
authors.lastname: Zhang
authors.affiliation: Department of General Surgery, Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People's Republic of China. yaohongliang08@outlook.com.
authors.forename: H
authors.initials: H
authors.lastname: Yao
authors.affiliation: Research Laboratory of Hepatobiliary Diseases, Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People's Republic of China.
authors.forename: Z
authors.initials: Z
authors.lastname: Yang
authors.affiliation: Department of Pathology, Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People's Republic of China.
authors.forename: D
authors.initials: D
authors.lastname: Li
authors.affiliation: Research Laboratory of Hepatobiliary Diseases, Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People's Republic of China.
authors.forename: L
authors.initials: L
authors.lastname: Yang
authors.affiliation: Department of Pathology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, People's Republic of China.
authors.forename: Q
authors.initials: Q
authors.lastname: Zou
authors.affiliation: Department of Pathology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, People's Republic of China.
authors.forename: Y
authors.initials: Y
authors.lastname: Yuan
authors.affiliation: Research Laboratory of Hepatobiliary Diseases, Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People's Republic of China.
authors.forename: X
authors.initials: X
authors.lastname: Miao
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000556:secondary*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D021441:Carcinoma, Pancreatic Ductal / Q000378:metabolism / Q000556:secondary*; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006360:Heat-Shock Proteins / Q000378:metabolism*; D006801:Humans; D007124:Immunoenzyme Techniques; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000378:metabolism / Q000473:pathology*; D011379:Prognosis; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D015996:Survival Rate; D000099200:Scaffold Protein ILK
chemical_list: D014408:Biomarkers, Tumor; D006360:Heat-Shock Proteins; D017346:Protein Serine-Threonine Kinases; D000099200:Scaffold Protein ILK; C491738:ERP29 protein, human
keywords: Chronic pancreatitis; ERP29; ILK; Immunohistochemistry; Pancreatic ductal adenocarcinoma; Pancreatic intraepithelial neoplasia